Drug Profile


Alternative Names: INT-5A2

Latest Information Update: 20 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator InteRNA Technologies
  • Class Antineoplastics; MicroRNAs
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatocellular carcinoma; Malignant melanoma

Highest Development Phases

  • Preclinical Hepatocellular carcinoma; Malignant melanoma

Most Recent Events

  • 20 Jul 2016 INT 5A2 is available for licensing as of 20 Jul 2016.
  • 20 Jul 2016 Preclinical trials in Hepatocellular carcinoma in Netherlands (unspecified route)
  • 20 Jul 2016 Preclinical trials in Malignant melanoma in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top